tivozanib — United Healthcare

Initial criteria

• Diagnosis of advanced renal cell carcinoma (RCC)
• AND
• Disease has relapsed OR Disease is refractory
• AND
• Patient has received two or more prior systemic therapies

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Fotivda therapy

Approval duration

12 months